Gilead Sciences extended its artificial intelligence and DevOps partnership with Cognizant for another five years. The agreement aims to expand AI use across the company’s business and IT operations.
Gilead also expanded its oncology research collaboration with Nurix Therapeutics, reinforcing its focus on cancer drug discovery. The moves support the company’s strategy to improve research productivity and grow its oncology portfolio alongside its established HIV franchise.
In related news, Cantor Fitzgerald reaffirmed its “overweight” rating on Gilead that day, while RBC Capital raised its price target. The collaborations and analyst actions reflect confidence in the company’s strategy and innovation pipeline.